1.天津中医药大学第一附属医院/中医国家临床医学研究中心,天津 300193
2.天津医科大学 第二医院泌尿外科,天津 300211
3.宁夏回族自治区中医医院科研处,银川 750021
廖智慧,男,25岁,硕士研究生。研究方向:中西结合治疗男科疾病。
陈少峰,E-mail:chenshaofeng1934@163.com
收稿:2025-10-13,
纸质出版:2026-03-25
移动端阅览
廖智慧,封玉宏,吴巍,等.苦参通关丸通过调控miRNA21/NF-κB/COX2信号通路介导铁死亡治疗良性前列腺增生的作用机制研究[J].北京中医药,2026,45(3):295-300.
LIAO Zhihui,FENG Yuhong,WU Wei,et al.Clinical efficacy of Kushen Tongguan Pills in the treatment of benign prostatic hyperplasia by regulating miRNA21/NF-κB/COX-2 signaling pathway to mediate ferroptosis[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(03):295-300.
廖智慧,封玉宏,吴巍,等.苦参通关丸通过调控miRNA21/NF-κB/COX2信号通路介导铁死亡治疗良性前列腺增生的作用机制研究[J].北京中医药,2026,45(3):295-300. DOI: 10.16025/j.1674-1307.2026.03.002.
LIAO Zhihui,FENG Yuhong,WU Wei,et al.Clinical efficacy of Kushen Tongguan Pills in the treatment of benign prostatic hyperplasia by regulating miRNA21/NF-κB/COX-2 signaling pathway to mediate ferroptosis[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(03):295-300. DOI: 10.16025/j.1674-1307.2026.03.002.
目的
2
探讨苦参通关丸对良性前列腺增生(BPH)患者的临床疗效及其潜在作用机制,验证其是否与调节微小RNA21(miRNA21)/核因子κB(NF-κB)/环氧化酶-2(COX2)信号通路介导的铁死亡有关。
方法
2
选取2025年6月—2025年10月于天津中医药大学第一附属医院男科门诊就诊的64例BPH患者,采用随机数字表法分为观察组和对照组,每组32例,研究过程中2组各脱落2例,最终各完成30例。观察组予苦参通关丸颗粒剂治疗,对照组予剂量为观察组10%的安慰剂治疗,疗程均为4周。治疗前后分别评估2组患者国际前列腺症状评分(IPSS)和中医证候积分;采用酶联免疫吸附试验(ELISA)检测前列腺液(EPS)中谷胱甘肽过氧化物酶4(GPx4)、COX2、超氧化物歧化酶(SOD)、丙二醛(MDA)、NF-κB p65、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平;采用聚合酶链反应(PCR)检测EPS中miRNA21表达水平。
结果
2
治疗后,观察组IPS
S、中医证候积分均较治疗前及对照组降低(
P
<
0.05)。与对照组比较,观察组EPS中GPx4、SOD水平升高(
P
<
0.05),而COX2、MDA、NF-κB p65、IL-6、TNF-α及miRNA21表达水平均显著降低(
P
<
0.05)。2组均未发生严重不良事件。
结论
2
苦参通关丸能有效改善BPH患者的临床症状,其机制可能与下调miRNA21表达、抑制NF-κB/COX2信号通路活性、调节铁死亡相关指标(GPx4、MDA)、减轻炎症反应(IL-6、TNF-α)与氧化应激损伤(SOD)有关。
Objective
2
To investigate the clinical efficacy of
Kushen Tongguan Pills
in patients with benign prostatic hyperplasia (BPH) and to explore its potential mechanisms of action, with emphasis on whether it is related to regulation of the miRNA21/NF-κB/COX-2 signaling pathway mediated ferroptosis.
Methods
2
A total of 64 BPH patients treated in the Male Outpatient Department of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from June 2025 to October 2025 were enrolled. Patients were randomly assigned to an observation group and a control group using a random number table, with 32 cases in each group. During the study, 2 cases in each group were lost to follow-up, and 30 cases in each group completed the trial. The observation group received
Kushen Tongguan Pill
granules, while the control group received a placebo at 10% of the dosage of the observation group. The treatment course was 4 weeks. Before and after treatment, International Prostate Symptom Score (IPSS) and traditional Chinese medicine (TCM) syndrome scores were evaluated. Enzyme-linked immunosorbent assay (ELISA) was used to detect levels of glutathione peroxidase 4 (GPx4), cyclooxygenase-2 (COX-2), superoxide dismutase (SOD), malondialdehyde (MDA), nuclear factor-κB p65 (NF-κB p65), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in expressed prostatic secretion (EPS). Polymerase chain reaction (PCR) was used to determine miRNA21 expression in EPS.
Results
2
After treatment, IPSS and TCM syn
drome scores in the observation group were significantly lower than those before treatment and those in the control group (
P
<
0.05). Compared with the control group, the observation group showed significantly increased levels of GPx4 and SOD in EPS (
P
<
0.05), while levels of COX-2, MDA, NF-κB p65, IL-6, TNF-α, and miRNA21 expression were significantly decreased (
P
<
0.05). No serious adverse events occurred in either group.
Conclusion
2
Kushen Tongguan Pills
can effectively improve clinical symptoms in patients with BPH. Its mechanism may be related to downregulation of miRNA21 expression, inhibition of NF-κB/COX-2 signaling pathway activity, regulation of ferroptosis-related indicators (GPx4, MDA), and alleviation of inflammatory response (IL-6, TNF-α) and oxidative stress injury (SOD).
LANGAN RC . Men's health: benign prostatic hyperplasia [J ] . FP Essent , 2021 , 503 : 18 - 22 .
冯隽龙 , 王继升 , 代恒恒 , 等 . 基于数据挖掘分析李海松治疗良性前列腺增生症的用药特点与规律 [J ] . 北京中医药 , 2021 , 40 ( 8 ): 893 - 896 .
良性前列腺增生诊疗及健康管理指南 [J ] . 中华男科学杂志 , 2022 , 28 ( 4 ): 356 - 365 .
KALTSAS A , KRATIRAS Z , ZACHARIOU A , et al . Evaluating the impact of benign prostatic hyperplasia surgical treatments on sexual health [J ] . Biomedicines , 2024 , 12 ( 1 ): 110 .
王雄 , 高瞻 , 唐益文 , 等 . 从“阳化气,阴成形”理论认识良性前列腺增生症 [J ] . 北京中医药 , 2023 , 42 ( 5 ): 535 - 537 .
李春旭 , 耿强 , 陈斐然 , 等 . 苦参通关丸治疗BPH的疗效及安全性分析 [J ] . 继续医学教育 , 2023 , 37 ( 3 ): 145 - 148 .
中国中医药信息学会男科分会 . 良性前列腺增生症中西医结合多学科诊疗指南(2022版) [J ] . 中国男科学杂志 , 2022 , 36 ( 2 ): 96 - 102 .
中国中西医结合学会男科专业委员会 . 良性前列腺增生中西医结合诊疗指南(试行版) [J ] . 中华男科学杂志 , 2017 , 23 ( 3 ): 280 - 285 .
黄敏玉 , 黄群 , 吴军 , 等 . miR-150调控TGF-β1信号通路与慢性 非细菌性前列腺炎的相关性研究 [J ] . 右江民族医学院学报 , 2019 , 41 ( 5 ): 496 - 499,504 .
张春和 , 李曰庆 , 裴晓华 , 等 . 良性前列腺增生症中医诊治专家共识 [J ] . 北京中医药 , 2016 , 35 ( 11 ): 1076 - 1080 .
OU Y , ZHANG W . Obacunone inhibits ferroptosis through regulation of Nrf2 homeostasis to treat diabetic nephropathy [J ] . Mol Med Rep , 2025 , 31 ( 5 ): 135 .
LUO Z , ZHENG B , JIANG B , et al . Peiminine inhibits the IL-1β induced inflammatory response in mouse articular chondrocytes and ameliorates murine osteoarthritis [J ] . Food Funct , 2019 , 10 ( 4 ): 2198 - 2208 .
杨婧怡 , 王佳艺 , 张悦 , 等 . “知母-黄柏”药对研究进展 [J ] . 中华中医药学刊 , 2025 , 43 ( 6 ): 138 - 142 .
张倩 , 方国力 , 周逸雪 , 等 . 黄柏调控铁死亡治疗颅脑损伤的作用机制研究 [J ] . 通化师范学院学报 , 2026 , 47 ( 2 ): 21 - 32 .
张宇 , 赵娜娜 , 吴伟民 . 肉桂醛调节RhoA/ROCK信号通路对急性胰腺炎大鼠肠道免疫功能的影响 [J ] . 现代免疫学 , 2025 , 45 ( 2 ): 143 - 150 .
薛桂凤 , 沈思瑶 , 曾晓春 . PI3K/AKT信号通路与良性前列腺增生的研究进展 [J ] . 中国中西医结合外科杂志 , 2024 , 30 ( 2 ): 289 - 293 .
ZHAN M , XU H , YU G , et al . Androgen receptor deficiency-induced TUG1 in suppressing ferroptosis to promote benign prostatic hyperplasia through the miR-188-3p/GPX4 signal pathway [J ] . Redox Biol , 2024 , 75 : 103298 .
杨梅柳 , 虞武 , 解燕昭 , 等 . 铁死亡和相关miRNA在缺血性脑卒中的研究进展 [J ] . 现代电生理学杂志 , 2025 , 32 ( 2 ): 124 - 128, 封 3 .
WANG H , LIU X , CHEN Y , et al . The regulatory role of miR-21 in ferroptosis by targeting FTH1 and the contribution of microglia-derived miR-21 in exosomes to arsenic-induced neuronal ferroptosis [J ] . J Hazard Mater , 2024 , 478 : 135580 .
邵明峰 , 邹建安 , 余子强 , 等 . 前列腺癌患者外周血单个核细胞中miR-21表达及临床意义 [J ] . 临床军医杂志 , 2019 , 47 ( 8 ): 799 - 801,803 .
胡爽 , 辛传伟 , 余霞丽 , 等 . 消渴平合剂对糖尿病肾病db/db小鼠NF-κB、IL-6表达的影响 [J ] . 中国中医药科技 , 2021 , 28 ( 1 ): 21 - 24 .
张刚 , 李航 , 韩湘 , 等 . 沙巴棕辅助治疗对良性前列腺增生患者EGF和PGE2的影响 [J ] . 中国性科学 , 2019 , 28 ( 7 ): 19 - 23 .
魏宏宇 , 高卉 , 郑琳琳 , 等 . 健脾补肾化浊解毒方对5/6肾切除慢性肾衰竭大鼠NF-κB p65、TNF-α、IL-6、Col-Ⅳ表达的影响 [J ] . 现代中西医结合杂志 , 2025 , 34 ( 3 ): 306 - 311 .
杨振斌 , 王庆娜 , 杨超 , 等 . 榆苋方保留灌肠对大肠湿热型溃疡性结肠炎大鼠PXR/NF-κB信号通路及炎症因子的调控作用研究 [J ] . 北京中医药 , 2023 , 42 ( 8 ): 847 - 851 .
郑超 , 许丹 . 基于IL-6/STAT3信号通路探究益肾通癃汤对良性前列腺增生大鼠的改善作用及机制 [J ] . 中国老年学杂志 , 2025 , 45 ( 21 ): 5318 - 5323 .
田海军 , 徐冬 , 田安然 , 等 . 血清炎症指标水平与良性前列腺增生的相关性研究 [J ] . 华南国防医学杂志 , 2020 , 34 ( 1 ): 20 - 22,31 .
殷虎明 , 李纲 , 张学锋 , 等 . 前列腺组织学炎症程度及血清hs-CRP水平与BPH患者总前列腺体积、国际前列腺症状评分的关系 [J ] . 山东医药 , 2016 , 56 ( 23 ): 85 - 87 .
黄达坤 , 林峰 , 李海馨 , 等 . 电针联合热敏灸对良性前列腺增生患者血清PSA、TNF-α、IL-6、EGF的影响 [J ] . 中医学报 , 2019 , 34 ( 8 ): 1783 - 1787 .
SHAN M , ZHANG S , LUO Z , et al . Itaconate promotes inflammatory responses in tissue-resident alveolar macrophages and exacerbates acute lung injury [J ] . Cell Metab , 2025 , 37 ( 8 ): 1750 - 1765.e7 .
YIN W , WEN B , XIAO Y , et al . Protective effects of minocycline, a tetracycline antibiotic, on cytokine storm and oxidative stress in acute lung injury [J ] . Int Immunopharmacol , 2025 , 161 : 114975 .
STOCKWELL BR . Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications [J ] . Cell , 2022 , 185 ( 14 ): 2401 - 2421 .
赵凡莹 , 张红晓 , 李纳川 , 等 . 天麻素通过Nrf2/GPX4信号通路调控铁死亡对高血压合并血管性痴呆大鼠神经损伤的治疗作用观察 [J ] . 北京中医药 , 2024 , 43 ( 12 ): 1378 - 1384 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备 11010102006710号